Audit of Global Fund grants to Mali reveals significant progress in financial management and quality of services
Catastrophe in Venezuela imperils the achievement of the Global Fund Strategy (2017-2022), says new report
Venezuela is in the middle of an unprecedented, state-made, complex humanitarian emergency. The public health crisis, which is just a symptom of the larger unraveling that is unfolding, has reached extreme levels. Essentials like soap and gloves have vanished from hospital floors. Life-saving medications are sometimes only available on the black market and cost half a month’s wages.
In what has been hailed as a “breakthrough” and a “game changer,” a pricing agreement between the Bill and Melinda Gates Foundation and two generic drug companies will result in significant savings in the cost of antiretrovirals (ARVs). As a result of the agreement, starting in 2018 a state-of-the-art fixed dose combination ARV regimen will be available in 92 developing nations at a maximum cost of $75 per patient per year.
OIG audit of two Global Fund grants to Guinea finds significant weaknesses in supply chain management
Although Guinea has made significant progress in the fight against the three diseases, despite a challenging operating environment, there are significant weaknesses in supply chain management and there are areas related to managing grant implementation that require improvement. These were the findings of an audit of Global Fund grants to Guinea conducted by the Office of the Inspector General (OIG).
Several important HIV-related announcements were made in the last few weeks. We provide short summaries.
“The scales have tipped”
The Global Fund continues to show impressive gains with respect to the number of people receiving key HIV, TB and malaria services as a result of programs supported by the Fund. Some of the gains reflect increased uptake of services, while other gains are the result of better reporting.
A new database is being developed in Eastern Europe and Central Asia (EECA) containing information on antiretrovirals (ARVs) in use in 15 countries: Armenia, Azerbaijan, Belarus, Estonia, Georgia, Kazakhstan, Kyrgyzstan, Latvia, Lithuania, Moldova, Poland, the Russian Federation, Tajikistan, Ukraine and Uzbekistan.
The Global Fund, one of the main purchasers of generic antiretroviral (ARV) medicines for HIV patients in low- and middle-income countries, has dismissed concerns that the limited number of manufacturers tapped to supply these drugs could result in immediate or future shortages. Fund officials said systems are in place to forecast demand, deal with any supply disruptions and increase production to meet future need.
More than a month has passed since the exchange of letters between the Global Fund and the Venezuelan Network of Positive People (RVG+ in its Spanish acronym) concerning what Venezuelan civil society describe as “a humanitarian crisis.” Very little has happened in the interim, at least not that we can report publicly.